1. Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma. (December 2016) Authors: Janku, F.; Vergilio, J.A.; Salhia, B.; Fanale, M.; Oki, Y.; Huang, H.; Westin, J.; He, J.; Nahas, M.; Mughal, T.; Miller, V.; Stephens, P.; Raina, A.; Garrido-Laguna, I.; Meric-Bernstam, F.; Ross, J.; Liang, W. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY. (June 2017) Authors: Nastoupil, L.J.; Westin, J.; Fowler, N.; Fanale, M.; Samaniego, F.; Oki, Y.; Obi, C.; Cao, J.; Cheng, X.; Ma, M.; Wang, Z.; Chu, F.; Feng, L.; Zhou, S.; Davis, R.E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL. (June 2017) Authors: Fanale, M.; Engert, A.; Younes, A.; Armand, P.; Ansell, S.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; De Boer, J.P.; Kuruvilla, J.; Savage, K.J.; Trneny, M.; Rodig, S.; Shipp, M.; Kato, K.; Sumbul, A.; Farsaci, B.; Santoro, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE. (June 2017) Authors: Oki, Y.; Feldman, T.; Chihara, D.; Sanchez, L.; Fanale, M.; Connors, J.M.; Wong, S.; Savage, K.J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS. (12th June 2019) Authors: Jagadeesh, D.; Horwitz, S.; Bartlett, N.L.; Advani, R.; Jacobsen, E.; Duvic, M.; Gautman, A.; Rao, S.; Onsum, M.; Fanale, M.; Kim, Y. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY. (June 2017) Authors: Fowler, N.H.; Samaniego, F.; Turturro, F.; Neelapu, S.; Forbes, S.; Westin, J.; Fayad, L.; Fanale, M.; Feng, L.; Arafat, J.; Neal, E.; Hagemeister, F.; Nastoupil, L. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗